BiotechTube
Home/ImmunoMet Therapeutics/Dean J. Welsch, PhD
DJ

Dean J. Welsch, PhD

Interim Chief Executive Officer / Chief Scientific Officer

ImmunoMet Therapeutics

Therapeutic Areas

OncologyFibrosis

ImmunoMet Therapeutics Pipeline

DrugIndicationPhase
Lixumistat (IM156)Pancreatic CancerPhase 1b

Leadership Team at ImmunoMet Therapeutics

PL
Paul Lammers, M.D., M.Sc.
Executive Chairman of the Board
View full ImmunoMet Therapeutics profile